SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
November 14, 2023 07:15 ET
|
SAB Biotherapeutics, Inc.
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a...
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
November 09, 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
October 24, 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a...
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
October 19, 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG) ...
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
October 05, 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human...
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
October 02, 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
August 21, 2023 08:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
June 21, 2023 08:30 ET
|
SAB Biotherapeutics, Inc.
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target...
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
May 30, 2023 08:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
May 19, 2023 08:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically...